Pauline Brice

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner et al. · The Lancet · 2010 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +6

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2017 · 985 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

Pauline Brice, Y Bastion, Éric Lepage et al. · Journal of Clinical Oncology · 1997 · 641 citations

Medicine, Hematology, Oncology +13

Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease

Christophe Fermé, Houchingue Eghbali, J.H. Meerwaldt et al. · New England Journal of Medicine · 2007 · 446 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study

Corinne Haïoun, Éric Lepage, Christian Gisselbrecht et al. · Journal of Clinical Oncology · 2000 · 422 citations

Medicine, Oncology, Chemotherapy +15